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Sirtuin 2 (SIRT2) is one of seven members of the 
NAD+-dependent histone deacetylases (HDAC) family 
of proteins. Sirtuins play diverse roles in cellular 
metabolism and the aging process. SIRT2 is located in 
the nucleus, cytoplasm, and mitochondria, is highly 
expressed in the central nervous system (CNS), and has 
been reported to regulate a variety of processes 
including oxidative stress, genome integrity, and 
myelination [1]. 
Very recently, we and others found that Sirt2-/- mice 
display an alteration of mitochondrial content and 
morphology, which results in energy failure and redox 
dyshomeostasis in the CNS [2-3].The axonal degenera-
tion accompanied by redox/mitochondrial dysfunction 
in aged Sirt2-/- mice [2], is also found in most of the 
age-related neurodegenerative disorders such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), or 
Amyotrophic Lateral Sclerosis (ALS), as well in 
common and rare diseases of myelin [4] and in 
physiological aging. This suggests that SIRT2 may play 
a role in the pathogenesis of these disorders, which may 
have strong therapeutic value. Furthermore, the effects 
of SIRT2 on myelination are intriguing, and have been 
examined in vivo in the peripheral nervous system, 
showing that both absence or overexpression are 
detrimental (Beirowski et al. 2011). This illustrates that 
tight control of Sirt2 dosage is a critical factor for 
successful myelin formation. The same is true con-
cerning oligodendroglial precursor cell cultures, which 
show a time and dosage-dependent control of SIRT2 
expression during differentiation, mediated by QKI 
proteins (Thangaraj et al. 2017). 
In the last 10 years, it has been suggested that SIRT1 
and SIRT2 play in a yin-yang relationship in which 
either activation of SIRT1 or inhibition of SIRT2, 
produced beneficial effects on neurodegenerative 
disorders [1]. However, in the light of recent reports 
indicating that inhibition of SIRT2 is either detrimental 
or has no positive effects on neurodegenerative disor-
ders such as ALS or cerebral ischemia [1], the fact that 
pharmacological and/or genetic inhibition of SIRT2 
ameliorates pathology in models of AD and PD raises a 
double question: What is the molecular basis for this 
selectivity? Why were no deleterious effects observed 
in the latter models? 
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The first answer appears straight-forward: In PD, 
inhibition of SIRT2 reduces α-synuclein aggregation 
and toxicity by modifying the levels of acetylation of 
this protein [5]; in AD, SIRT2 is abnormally over-
expressed and deacetylates tubulin which results in 
microtubule destabilization, Tau dissociation from 
microtubules, and subsequent oligomerization and 
aggregate formation [6]. Thus, SIRT2 seems to act 
directly on the cause instead of the downstream con-
sequences of the pathology, i.e redox homeostasis and 
mitochondria malfunction, in both PD and AD models 
in which there were no obvious deleterious effects due 
to Sirt2 reduction. However, we have also shown that 
SIRT2 is important for dopaminergic differentiation 
(Szego et al. 2017), and that it can suppress microglial 
activation and brain inflammation [1]. These findings 
suggest that SIRT2 may play different roles in different 
cell types and during different stages of development/ 
aging. In addition, other possibilities may account for 
the differential effects of modulating SIRT2: i) a 
compensatory effect leading to increased SIRT1 
expression, as shown in our study [2], a non-negligible 
phenomenon not explored in the AD and PD models 
described; or ii) a direct impact on the limited pool of 
NAD+, a main metabolic regulator linking cellular 
metabolism to changes in signaling and transcriptional 
events, through redox enzymatic reactions or through 
NAD+-consuming enzymes such as sirtuins or PARP-1, 
among others [7]. 
In conclusion, the connection between SIRT2 and 
neurological disorders is now well established, and thus, 
the potential of SIRT2 as a therapeutic target deserves 
to be studied in greater depth. We believe that any 
positive results obtained with either activators or 
inhibitors of SIRT2 demands cautious investigation on 
the mechanisms and idiosyncrasies of each particular 
model, for optimizing translational efforts while 
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